Immunovant director granted RSUs and stock options
Immunovant, Inc. reported that director Douglas J. Hughes received new equity awards as part of his compensation.
Rhea-AI Filing Summary
Immunovant, Inc. reported that director Douglas J. Hughes received new equity awards as part of his compensation. He was granted 13,880 shares of Common Stock in the form of restricted stock units, bringing his direct holdings to 134,653 common shares after the grant.
He also received a stock option covering 7,061 shares of Common Stock at an exercise price of $24.61 per share. Both the RSUs and the option awards vest in full on April 1, 2027, subject to his continuous service with the company, and the options expire on April 7, 2036. The RSUs may be settled later at his election, subject to Rule 409A.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 20,941 shares
Grant/Award
2 txns
Insider
Hughes Douglas J.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 7,061 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 13,880 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 7,061 contracts (Direct);
Common Stock — 134,653 shares (Direct)
Footnotes (2)
- F1. These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.
- F2. These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date.
Key Figures
RSU grant: 13,880 shares
Option grant size: 7,061 shares
Option exercise price: $24.61 per share
+3 more
6 metrics
RSU grant
13,880 shares
Restricted stock units granted April 7, 2026; vest April 1, 2027
Option grant size
7,061 shares
Stock option covering common shares granted April 7, 2026
Option exercise price
$24.61 per share
Exercise price for stock options granted to director
Option expiration
April 7, 2036
Expiration date of the newly granted stock options
Shares held after grant
134,653 shares
Director’s direct Immunovant common stock holdings after RSU grant
RSU vesting date
April 1, 2027
Vesting date for both RSUs and underlying option shares
Key Terms
restricted stock units ("RSUs"), 2019 Equity Incentive Plan, Rule 409A, stock option
4 terms
restricted stock units ("RSUs") financial
"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2019 Equity Incentive Plan financial
"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan"
Rule 409A financial
"The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A."
stock option financial
"These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did Immunovant (IMVT) director Douglas J. Hughes receive?
Douglas J. Hughes received two equity awards: 13,880 restricted stock units and a stock option for 7,061 shares at $24.61 per share. These awards are part of his compensation and align his interests with Immunovant’s long-term performance.
When do Douglas J. Hughes’ new Immunovant RSUs and options vest?
Both the 13,880 restricted stock units and the stock options for 7,061 shares vest in full on April 1, 2027. Vesting requires Hughes to remain in continuous service with Immunovant through that date under the company’s 2019 Equity Incentive Plan.
What is the exercise price and expiration date of Douglas J. Hughes’ Immunovant options?
The newly granted stock options allow Douglas J. Hughes to buy 7,061 Immunovant shares at $24.61 per share. These options were granted under the 2019 Equity Incentive Plan and are scheduled to expire on April 7, 2036, if not exercised earlier after vesting.
Can Douglas J. Hughes defer settlement of his Immunovant RSUs after vesting?
Yes. The filing states Hughes may elect to defer settlement of his restricted stock units upon vesting, subject to Rule 409A requirements. This means he can delay when he actually receives the underlying Immunovant common shares for tax or planning reasons.
AI-generated analysis. How Rhea-AI works. Not financial advice.
